Consensus: 10 Analysts covering Achillion recommend purchasing its shares and two recommend holding them.
Roth Capital Partners has a buy rating and $12 price target on Achillion, which calls for quite a bit of upside based on current levels. "Achillion's strong clinical performance with ACH-1625 to-date, we believe should be of strong interest to investors looking to be involved in the Hepatitis C virus (HCV) space. We believe the drug's profile to-date make it a very attractive partnering candidate," the firm wrote in a research note late last month.
ACHN.nasdaq 2.55$
Aucun commentaire:
Enregistrer un commentaire